Application of Telemedicine in Diabetes Care: The Time is Now Felix AbererDaniel A. HochfellnerJulia K. Mader Commentary Open access 20 January 2021 Pages: 629 - 639
What is Diabetes Remission? Jens J. HolstSten Madsbad Commentary Open access 20 February 2021 Pages: 641 - 646
What’s in a Name? Redefining Type 2 Diabetes Remission Sanjay KalraArbinder SingalTejal Lathia Review Open access 24 January 2021 Pages: 647 - 654
Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study Yuta YoshizawaMichihiro HosojimaAkihiko Saito Original Research Open access 20 January 2021 Pages: 655 - 667
Skin Autofluorescence in Young Adult Offspring of Women with Type 1 Diabetes: A Cross-Sectional Case–Control Study Cedric KorpijaakkoNiko WaseniusMerja K. Laine Original Research Open access 23 January 2021 Pages: 669 - 677
The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India Sanjay KalraA. G. UnnikrishnanKumar Gaurav Original Research Open access 28 January 2021 Pages: 679 - 695
Risk Factors for Albuminuria in Normotensive Older Adults with Type 2 Diabetes Mellitus and Normal Renal Function: A Cross-Sectional Study Yingyi ZhouKe ChenBimin Shi Original Research Open access 29 January 2021 Pages: 697 - 705
Movement is Improvement: The Therapeutic Effects of Exercise and General Physical Activity on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Sayed Z. A. ShahJawad A. KaramHong Chen Original Research Open access 05 February 2021 Pages: 707 - 732
Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study Martin PfohlJochen SeufertThorsten Siegmund Original Research Open access 05 February 2021 Pages: 733 - 747
Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study Jochen SeufertMartin PfohlThorsten Siegmund Original Research Open access 05 February 2021 Pages: 749 - 764
Impact of Intensive Glucose Control on Brain Health: Meta-Analysis of Cumulative Data from 16,584 Patients with Type 2 Diabetes Mellitus Xingyao TangMarly A. CardosoRafael Simó Original Research Open access 06 February 2021 Pages: 765 - 779
Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies Gian Paolo FadiniOlga DisoteoAgostino Consoli Original Research Open access 07 February 2021 Pages: 781 - 800
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study David M. WilliamsAliya M. RuslanThinzar Min Original Research Open access 09 February 2021 Pages: 801 - 811
Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial Liming ChenQiuling XingLaurence J. Hirsch Original Research Open access 11 February 2021 Pages: 813 - 826
Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes Tomoki FujikawaMakoto OharaSho-ichi Yamagishi Original Research Open access 13 February 2021 Pages: 827 - 842
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Haleh ChehrehgoshaMasoud Reza SohrabiMohammad E. Khamseh Original Research Open access 14 February 2021 Pages: 843 - 861
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial Hiroaki Seino Original Research Open access 16 February 2021 Pages: 863 - 877
Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study Ildiko LingvayAndreas R. KirkJay H. Shubrook Original Research Open access 17 February 2021 Pages: 879 - 896
Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes Yoshio NagaiKiyoyasu KazumoriYasushi Tanaka Original Research Open access 17 February 2021 Pages: 897 - 911
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study Zdravko KamenovVeselina PehlivanovaSvetla Mihalevska Original Research Open access 19 February 2021 Pages: 913 - 930
A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience Tianshu ZengHuijuan YuanLinong Ji Original Research Open access 22 February 2021 Pages: 931 - 941
Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study Matthias HepprichDaniela ZilligGottfried Rudofsky Original Research Open access 22 February 2021 Pages: 943 - 954
Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study) Hiroshi NomotoChiho Oba-YamamotoHideaki Miyoshi Study Protocol Open access 24 January 2021 Pages: 955 - 964